300601.SZ
康泰生物
SZSE · Healthcare · C 制造业 · CN
CNY 12.62
−3.15%Year over year
Reported trailing growth
- Revenue
- -6.5%
- EBITDA
- —
- EBIT
- -63.7%
- EPS
- -54.1%
- Free cash flow
- +9.5%
- Operating cash flow
- -8.0%
Forward estimates
Based on analyst estimates
- Revenue
- +6.2%
- EBITDA
- +78.0%
- EPS
- +152.5%
Three-year CAGR
- Revenue
- -5.4%
- EBITDA
- -37.0%
- EBIT
- -80.0%
- Net income
- -71.4%
- EPS
- -72.1%
- Free cash flow
- -1.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026